Global Programme to Eliminate Lymphatic Filariasis ... - libdoc.who.int

1373.3.6a Report of MDA coverage by IUsRegion Name of IU MDAtypeMDA period Details of IUData reported by IUStartdateEnddateNo. ofvillagesin IUTotal pop. in villages a No. ofurbanareas inIUTotalpop. inurbanareasin IUTotal pop. of IU a Eligible pop. of IU b No. of poplewhodrugs b pop. pop. covered areas villages urban(%) cingested % of No. of % of drugs d drugs fingested ingestedin IU in IU g coveredthe total eligible villages urban total totalwho who in IU covered covered areasthe thein IU he e.g. 80[65—95%]TOTALaFor calculation of overall coverage, use the total population as denominator. Census data or estimates of total population enumerated by drug distributors can be used.bIn areas where DEC and albendazole are administered, the eligible population = total population minus pregnant women, children under 2 years and the severely ill. In areas where ivermectin and albendazoleare administered, the eligible population = total population minus pregnant women, women in the first week of lactation, children under 90 cm or 15 kg, and the severely ill.cDrug coverage is calculated as a percentage of the total population as well as of the eligible population who ingested the drugs. This coverage is evaluated by year and by MDA period. It can be calculated foreach IU from reports received from reporting units or drug distributors.dNo. of people who ingested the drugs/total population in IU x 100.eCountry coverage reported (% of variation of coverage): give in brackets the minimal and maximal coverage reported in the IU.fNo. of people who ingested the drugs/eligible population in IU x 100.gNo. of villages covered/no. of villages in IU x 100.hNo. of urban areas covered/no. of urban areas in IU x 100.ANNEXES Annex 2 Revised Annual Report FormAnnual Report on Lymphatic Filariasis 2003